Report an error   


Submitted: 04 February 2014 Modified: 13 June 2014
HERDIN Record #: R04A-DLSHSI-14020411513887

Ivabradine Usage and Association with In-hospital Mortality in Acute Coronary Syndrome Patient’s Admitted to DLSUMC from January 2011 – May 2013

See More

Background : According to American Heart Association (AHA) survey approximately 18% of men and 23% of women over the age of 40 will die within 1 year of having an initial recognized Myocardial Infarction (MI). Heart rate is detrimental in Coronary Artery Disease (CAD). It is known as determinant of infarct size i.e, a reduction in HR of at least 15 beats/min is associated with a reduction of infarct size (25% to 30%)

Objectives: This study aims to determine the proportion of ACS patients who were given ivabradine and determine the association of ivabradine treatment and inpatient mortality.

Methods: This was a cross sectional study, included all patients diagnosed with Acute Coronary Syndrome from January 1, 2012 - May 31, 2013 in DLSUMC, a tertiary hospital. Data were collected using standardized data collection sheet and analyzed using descriptive statistics and association.

Results: A total number of 324 Acute Coronary Syndrome patients from January 2012 to May 2013 were included in this study. Most of the patient in the ivabradine group classified as Killips class III severity 39.2%, while the control group was dominated with cases of Killips class I severity 52.3% (p=<0.0001). The use of Beta-blocker was noted higher in the non ivabradine group 16.7% vs 26.6% in the ivabradine group (p: 0.018). Overall inpatient mortality rate in both groups was 16.4%.

Conclusion: This study found that ivabradine was used in 31.5% patients with ACS. The trends of inhospital death were lower in the ivabradine group (15.6% vs 16.7%. p:0.825). The authors suggest further larger and placebo-controled study are required to determine ivabradine effect on inpatient mortality and other clinical outcomes in patient with ACS.

Objectives

Objectives: This study aims to determine the proportion of ACS patients who were given ivabradine and determine the association of ivabradine treatment and inpatient mortality.

LocationLocation CodeAvailable FormatAvailability
3/F Room 6301 De La Salle Angelo King Medical Research Center Abstract Print Format